Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Type of study
Language
Year range
1.
Al-Shifa Journal of Ophthalmology. 2013; 9 (1): 29-33
in English | IMEMR | ID: emr-167922

ABSTRACT

To observe the difference in IOP that occurs before and after phacoemulsification surgery. A six month study was conducted at Department of Ophthalmology, Unit A, Khyber Teaching Hospital/ Khyber Medical College, Peshawar. Total number of 38 eyes were operated upon. Intraocular pressure was recorded using a Goldmann tonometer. One reading was taken one day before the scheduled operation and the second reading a day after. Universal II model from Alcon[registered sign] Surgical was used in the trial. Types of viscoelastic and IOL were also noted. Based on preoperative [pre-op] and postoperative [post-op] intraocular pressure, they were placed in 2 groups Within the 2 groups, the increase in IOP was statistically significant 24 hours after surgery. Between the groups, the difference was highly significant [P =.003], as determined by Pearson's Correlation test. The increase in IOP was higher in the Viscoat group, 14.28%, as compared to the Hydroxypropyl methylcellulose [HPMC] group, 7.14%. Mean IOP was 14.71 mmHg after surgery as compared to 12.42 mmHg preoperatively. Out of 38 patients 4 [10.5%] had pressures above 20 mmHg. The transient increase in post-op IOP was highly significant 24 hours after surgery in cases where HPMC and Viscoat were used. In cases where Provisc was used no significant elevation of IOP was noted

2.
Al-Shifa Journal of Ophthalmology. 2012; 8 (1): 28-35
in English | IMEMR | ID: emr-181551

ABSTRACT

Purpose: To determine the clinical indications of enucleation surgery at Al-Shifa Trust Eye Hospital Rawalpindi


Participants and Methodology: An observational case series was carried out for the study being conducted at Al-Shifa Trust Eye Hospital, Rawalpindi in which 60 new cases undergoing enucleation during 6 months were included by non probability convenience sampling


Results: There were 31[51.7%] male and 29 [48.3%] female patients with a mean age of 23.51[SD 19.546] years. Malignant tumours [41.66% eyes] were the most common indication of enucleation followed by phthisis bulbi [23.33% eyes] and trauma [16.7% eyes]. Retinoblastoma [RB] was found to be the most common malignant tumour diagnosed in 20% eyes. Students comprised 28.33% of the cases followed by farmers / laborers [23.33%] and housewives [13.33%]. In terms of socioeconomic status 37 [61.66%] patients belonged to lower class


Conclusion: Advanced ocular malignancies, phthisis bulbi and traumatically shattered eye globes are the major indications for enucleation in our country. Protective measures from trauma, early detection of tumours and creating awareness at various levels can decrease the incidence of enucleation

3.
Al-Shifa Journal of Ophthalmology. 2011; 7 (2): 88-93
in English | IMEMR | ID: emr-130265

ABSTRACT

To determine efficacy of single intravitreal injection of bevacizumab [Avastin] for treatment of clinically significant macular edema [CSME]. A quasi experimental month study was carried out at the retina clinic of Al Shifa Trust Eye Hospital, Rawalpindi from 1[st] January 2010 to 31[st] December 2010. A total 107 patients with CSME were included in this study. All patients were evaluated for visual acuity, anterior and posterior segment while central macular thickness was documented through optical coherence tomography. A single injection of bevacizumab was administered in all the patients. Outcome measures [improvement in BCVA and decrease in central retinal thickness] were evaluated at 2 weeks, 1 month and 2 months. All except one patient completed 2 months of follow-up. At baseline mean BCVA +/- SD was 0.967591 +/- 0.3705 log MAR of Snellen letters, which significantly improved to 0.808525 +/- 0.3260 at 2 weeks, 0.65581 +/- 0.36078 at 1 month, and 0.6319 +/- 0.3900 at 2 months [for each, p-value < 0.05]. The mean central retinal thickness +/- SD was 502.60 +/- 81.622microm at baseline and significantly decreased to 307.69 +/- 82.306 microm at 2 weeks, 235.75 +/- 63.162 microm at 1 month, and 237.58 +/- 64.230 microm at 2 months [for each, p-value < 0.05]. Primary single intravitreal bevacizumab injection in a concentration of 1.25mg / 0.05ml in patients with CSME resulted in significant improvement in BCVA and central macular thickness as early as 2 weeks after injection, and this beneficial effect persisted for up to 2 months


Subject(s)
Humans , Female , Male , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal, Humanized/administration & dosage , Intravitreal Injections , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL